Ernesto Mejías-Pérez

Ernesto Mejías-Pérez

Auto-generated profile, based on publicly available information

Ernesto Mejías-Pérez

Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PWPaul R. Wratil
Paul R. Wratil
MSMarcel Stern
Marcel Stern
APAlina Priller
Alina Priller
AWAnnika Willmann
Annika Willmann
GAGiovanni Almanzar
Giovanni Almanzar
Ulrike ProtzerUlrike Protzer
Ulrike Protzer

6 December 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MAManuel Albanese
Manuel Albanese
YCYen-Fu Adam Chen
Yen-Fu Adam Chen
CHCorinna Hüls
Corinna Hüls
KGKathrin Gärtner
Kathrin Gärtner
TTTakanobu Tagawa
Takanobu Tagawa
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Mammalian cells release different types of vesicles, collectively termed extracellular vesicles (EVs). EVs contain cellular microRNAs (miRNAs) with an apparent potential to deliver their miRNA cargo to recipient cells to affect the stability of individual mRNAs and the cells’ transcriptome. The extent to which miRNAs are exported via the EV route and whether they contribute to cell-cell communication are controversial. To address these issues, we defined multiple properties of EVs and analyzed their capacity to deliver packaged miRNAs into target cells to exert biological functions. We applied well-defined approaches to produce and characterize purified EVs with or without specific viral miRNAs. We found that only a small fraction of EVs carried miRNAs. EVs readily bound to different target cell types, but EVs did not fuse detectably with cellular membranes to deliver their cargo. We engineered EVs to be fusogenic and document their capacity to deliver functional messenger RNAs. Engineered fusogenic EVs, however, did not detectably alter the functionality of cells exposed to miRNA-carrying EVs. These results suggest that EV-borne miRNAs do not act as effectors of cell-to-cell communication.

23 December 2021 in Nature Methods
Verified
Journal Article
Open access
PDF file
MAManuel Albanese
Manuel Albanese
ARAdrian Ruhle
Adrian Ruhle
JMJennifer Mittermaier
Jennifer Mittermaier
EMErnesto Mejías-Pérez
Ernesto Mejías-Pérez
MGMadeleine Gapp
Madeleine Gapp
OKOliver T. Keppler
Oliver T. Keppler
CD4+T cells are central mediators of adaptive and innate immune responses and constitute a major reservoir for human immunodeficiency virus (HIV) in vivo. Detailed investigations of resting human CD4+T cells have been precluded by the absence of efficient approaches for genetic manipulation limiting our understanding of HIV replication and restricting efforts to find a cure. Here we report a method for rapid, efficient, activation-neutral gene editing of resting, polyclonal human CD4+T cells using optimized cell cultivation and nucleofection conditions of Cas9–guide RNA ribonucleoprotein complexes. Up to six genes, including HIV dependency and restriction factors, were knocked out individually or simultaneously and functionally characterized. Moreover, we demonstrate the knock in of double-stranded DNA donor templates into different endogenous loci, enabling the study of the physiological interplay of cellular and viral components at single-cell resolution. Together, this technique allows improved molecular and functional characterizations of HIV biology and general immune functions in resting CD4+T cells.

12 August 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
FTFranziska R. Traube
Franziska R. Traube
MSMarcel Stern
Marcel Stern
ATAnnika J. Tölke
Annika J. Tölke
MRMartina Rudelius
Martina Rudelius
EMErnesto Mejías‐Pérez
Ernesto Mejías‐Pérez
TCThomas Carell
Thomas Carell
The emergence of more transmissible or aggressive variants of SARS‐CoV‐2 requires the development of antiviral medication that is quickly adjustable to evolving viral escape mutations. Here we report the synthesis of chemically stabilized small interfering RNA (siRNA) against SARS‐CoV‐2. The siRNA can be further modified with receptor ligands such as peptides using CuI‐catalysed click‐chemistry. We demonstrate that optimized siRNAs can reduce viral loads and virus‐induced cytotoxicity by up to five orders of magnitude in cell lines challenged with SARS‐CoV‐2. Furthermore, we show that an ACE2‐binding peptide‐conjugated siRNA is able to reduce virus replication and virus‐induced apoptosis in 3D mucociliary lung microtissues. The adjustment of the siRNA sequence allows a rapid adaptation of their antiviral activity against different variants of concern. The ability to conjugate the siRNA via click‐chemistry to receptor ligands facilitates the construction of targeted siRNAs for a flexible antiviral defence strategy.

26 August 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LSLucía Suanes-Cobos
Lucía Suanes-Cobos
IAIrene Aguilera-Ventura
Irene Aguilera-Ventura
MTMiguel Torres-Ramos
Miguel Torres-Ramos
ASAlejandra Serrano-Yubero
Alejandra Serrano-Yubero
CFClaudia Moreno Fernández-Aliseda
Claudia Moreno Fernández-Aliseda
MCMarco Antonio Calzado Canale
Marco Antonio Calzado Canale
Posttranslational modifications, such as ubiquitination and phosphorylation, play pivotal roles in regulating protein stability in response to cellular stress. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and ubiquitin-specific peptidase 28 (USP28) are critical regulators of cell cycle progression, DNA damage response, and oncogenic signaling. However, their functional interplay remains largely unexplored. Here, we describe a novel bidirectional regulatory mechanism between DYRK2 and USP28 that integrates DNA damage response and ubiquitin-mediated protein degradation. We demonstrate that DYRK2 phosphorylates USP28, promoting its ubiquitination and proteasomal degradation in a kinase activity-independent manner, thereby contributing to the maintenance of oncogenic protein homeostasis. Conversely, USP28 functions as a deubiquitinase for DYRK2, stabilizing its protein levels and enhancing its kinase activity. Notably, we show that DYRK2 interacts and co-localizes with USP28, with the 521–541 DYRK2 region, particularly residue T525, playing a crucial role in USP28-mediated DYRK2 stabilization. Functionally, this reciprocal regulation modulates p53 signaling, influencing apoptotic responses to DNA damage. DYRK2-mediated phosphorylation of p53 at S46 is significantly reduced upon USP28 depletion, suggesting that USP28 facilitates DYRK2-dependent apoptosis. Additionally, our results highlight a complex regulatory axis involving USP28 and DYRK2, with implications for oncogenic cell death and genomic stability. Overall, our findings uncover a novel feedback loop in which DYRK2 and USP28 dynamically regulate each other to control proto-oncoprotein homeostasis and DNA damage signaling. This interplay offers potential therapeutic opportunities for targeting cancers with dysregulated ubiquitination and genomic instability.

12 August 2022 in Angewandte Chemie
Verified
Journal Article
Open access
FTFranziska R. Traube
Franziska R. Traube
MSMarcel Stern
Marcel Stern
ATAnnika J. Tölke
Annika J. Tölke
MRMartina Rudelius
Martina Rudelius
EMErnesto Mejías‐Pérez
Ernesto Mejías‐Pérez
TCThomas Carell
Thomas Carell
Die Entstehung von leichter übertragbaren oder aggressiveren Varianten von SARS‐CoV‐2 erfordert die Entwicklung von antiviralen Medikamenten, die schnell an sich entwickelnde virale Escape‐Mutationen anpassbar sind. Hier berichten wir über die Synthese von chemisch stabilisierter small interfering RNA (siRNA) gegen SARS‐CoV‐2. Die siRNA kann mit Hilfe von CuI‐katalysierter Klick‐Chemie mit Rezeptorliganden wie Peptiden zusätzlich modifiziert werden. Wir zeigen, dass optimierte siRNAs die Viruslast und die virus‐induzierte Zytotoxizität in Zelllinien, die mit SARS‐CoV‐2 infiziert sind, um bis zu fünf Größenordnungen reduzieren können. Darüber hinaus zeigen wir, dass eine mit einem ACE2‐bindenden Peptid‐konjugierte siRNA in der Lage ist, die Virusreplikation und die virus‐induzierte Apoptose in mukoziliären 3D‐Lungenmikrogeweben zu reduzieren. Eine Änderung der siRNA‐Sequenz ermöglicht eine schnelle Anpassung ihrer antiviralen Aktivität gegen verschiedene Virusvarianten. Die Möglichkeit, die siRNA mittels Klick‐Chemie an Rezeptorliganden zu konjugieren, erleichtert die Entwicklung zielgerichteter siRNAs für eine flexible antivirale Abwehrstrategie.